As patients with multiple sclerosis (MS) age, the risk of cancer also increases. Immune checkpoint inhibitors (ICIs) are novel monoclonal antibodies that have revolutionized cancer treatment. However, their use is limited by immune related adverse events. In patients with MS and pre-existing autoimmune disease there is concern that use of ICIs could worsen disease outcome. In the first part of this review we discuss the current data on ICIs and MS which overall suggest that they are well tolerated from the standpoint of MS disease activity. We recommend that MS not be a strict contraindication to ICI use which should depend on an individualized risk benefit discussion. In the second part, we focus on novel therapies for MS including CAR-T cell and anti-CD40L treatments. These newer therapies have the potential to address an unmet need in MS as they can cross the blood-brain and have the potential to target compartmentalized central nervous inflammation that may underly the pathophysiology of progressive MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neurot.2025.e00558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Insight into the Mechanism of Neurochemical Imbalance in Multiple Sclerosis: Abnormal Transportation of Brain Extracellular Space.
Aging Dis
March 2025
Department of Radiology, Peking University Third Hospital, Beijing, China.
Neurochemical imbalance is a contributing factor to neurological symptoms in multiple sclerosis (MS). The matured myelin sheath is crucial for substance transportation within the extracellular space (ECS) and for maintaining local homeostasis. Therefore, we hypothesize that disturbed ECS transportation following demyelinating lesions might lead to neurochemical imbalance in MS.
View Article and Find Full Text PDFVaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization.
Mult Scler
March 2025
Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background: Vaccination in patients with multiple sclerosis (PwMS) presents unique challenges. Disease-modifying therapies (DMTs) can increase infectious risks, though these are largely preventable through immunizations. However, DMTs can also reduce vaccine efficacy.
View Article and Find Full Text PDFFinal COVID-19 Vaccination Status, Attitude, and Adverse Events Among People With Multiple Sclerosis: A Cross-Sectional Study From Egypt.
Int J MS Care
January 2025
From the Department of Neurology, Alexandria University, Alexandria, Egypt.
Background: Until the World Health Organization declared an end to COVID-19 as a global health emergency worldwide in 2023, people with multiple sclerosis (MS) were hesitant to get the COVID-19 vaccine. This study aimed to assess the final vaccination status, attitude, and adverse events related to the COVID-19 vaccine among people with MS in Egypt.
Methods: A self-administered survey was offered to people with MS who came to the Alexandria University MS Clinic in Egypt between June 2023 and November 2023.
Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody-associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes.
Front Immunol
March 2025
Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan.
Background: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated diseases (MOGAD), which has been recognized as a distinct entity in patients with neuromyelitis optica spectrum disorders, often presents with acute disseminated encephalomyelitis (ADEM) symptoms in pediatric patients. Appropriate treatment based on accurate diagnosis is challenging in relapsing pediatric patients with MOGAD.
Case Presentation: An 11-year-old girl experienced relapses four times, exhibiting brainstem symptoms, an ADEM episode, seizures, and optic neuritis (ON).
Structural insights into SOD1: from in silico and molecular dynamics to experimental analyses of ALS-associated E49K and R115G mutants.
Front Mol Biosci
February 2025
Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Protein stability is a crucial characteristic that influences both protein activity and structure and plays a significant role in several diseases. Cu/Zn superoxide dismutase 1 (SOD1) mutations serve as a model for elucidating the destabilizing effects on protein folding and misfolding linked to the lethal neurological disease, amyotrophic lateral sclerosis (ALS). In the present study, we have examined the structure and dynamics of the SOD1 protein upon two ALS-associated point mutations at the surface (namely, E49K and R115G), which are located in metal-binding loop IV and Greek key loop VI, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!